Cargando…
PROX1 is a predictor of survival for gliomas WHO grade II
BACKGROUND: The clinical course of World Health Organisation grade II gliomas remains variable and their time point of transformation into a more malignant phenotype is unpredictable. Identification of biological markers that can predict prognosis in individual patients is of great clinical value. P...
Autores principales: | Elsir, T, Qu, M, Berntsson, S G, Orrego, A, Olofsson, T, Lindström, M S, Nistér, M, von Deimling, A, Hartmann, C, Ribom, D, Smits, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111172/ https://www.ncbi.nlm.nih.gov/pubmed/21559010 http://dx.doi.org/10.1038/bjc.2011.162 |
Ejemplares similares
-
Expression and prognostic value of transcription factor PROX1 in colorectal cancer
por: Skog, M, et al.
Publicado: (2011) -
Perfusion imaging with arterial spin labeling (ASL)–MRI predicts malignant progression in low‑grade (WHO grade II) gliomas
por: Flies, Christina M., et al.
Publicado: (2021) -
Prognostic value of increase in transcript levels of Tp73 ΔEx2-3 isoforms in low-grade glioma patients
por: Wager, M, et al.
Publicado: (2006) -
Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade
por: Burger, M, et al.
Publicado: (2007) -
Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma
por: Han, S, et al.
Publicado: (2014)